Literature DB >> 24623863

Evaluation of reasons for dabigatran discontinuation in a community hospital and anticoagulation clinic.

Ashley Jacobs1, Dustin Linn1, Brook Sipe1, Angel Heyerly2, Gordon Bokhart3.   

Abstract

Entities:  

Year:  2014        PMID： 24623863      PMCID： PMC3940675          DOI： 10.1310/hpj4902-115

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


× No keyword cloud information.
  3 in total

1.  Iron complex, dabigatran and toxic epidermal necrolysis syndrome: a case-report.

Authors:  A Tsoumpris; T Tzimas; K Gkabrelas; N Akritidis
Journal:  J Clin Pharm Ther       Date:  2012-12-12       Impact factor: 2.512

2.  Rash associated with dabigatran etexilate.

Authors:  Kim To; Carl Reynolds; Sarah A Spinler
Journal:  Pharmacotherapy       Date:  2013-02-11       Impact factor: 4.705

Review 3.  Medication adherence: its importance in cardiovascular outcomes.

Authors:  P Michael Ho; Chris L Bryson; John S Rumsfeld
Journal:  Circulation       Date:  2009-06-16       Impact factor: 29.690
  3 in total
  3 in total

Review 1.  Factors Affecting Patients' Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants.

Authors:  Ekta Y Pandya; Beata Bajorek
Journal:  Patient       Date:  2017-04       Impact factor: 3.883

Review 2.  Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation.

Authors:  Miney Paquette; Lawrence Mbuagbaw; Alfonso Iorio; Robby Nieuwlaat
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2021-05-23

3.  Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.

Authors:  Gregory Y H Lip; Xianying Pan; Shital Kamble; Hugh Kawabata; Jack Mardekian; Cristina Masseria; Hemant Phatak
Journal:  PLoS One       Date:  2018-04-30       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.